Supreme Court justices signaled that they could open up patent settlements between the makers of branded and generic drugs to increased scrutiny from the courts.
During arguments and questioning on Monday, Justice Anthony Kennedy discussed the possibility of limiting settlements to the amount of awards that makers of generic drugs could expect from a successful patent lawsuit.

Related Summaries